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Background: Current guidelines only recommend the use of mineralocorticoid receptor antagonists (MRA) in NYHA class >III. We used a meta-
analysis to quantify the improvement in EF with MRA therapy and to clarify whether this benefit is dependent on baseline NYHA.
Method: A MEDLINE search and examination of reference lists was used to identify randomized controlled trials of MRA where there was a clear 
description of baseline NYHA class and change in EF. Study characteristics, demographics, etiology, inclusion/exclusion criteria, echocardiograms 
and exercise capacity assessment at baseline and at completion were extracted. The primary outcome was change in EF. A separate analysis 
examined the influence of MRA on exercise capacity in trials which the primary outcome was measurable.
Results: Of 14 trials, 3 included patients with average NYHA class <II (244 patients), 8 involved NYHA II-III (979 patients) and 3 included NYHA 
≥3 (237 patients). Treatment duration was 7.7 months (range 2-12 months). Baseline EF and improvement were similar in NYHA<II (baseline EF 
33%, improvement 5%), NYHA II-III (34% and 4%) and NYHA >III (36% and 6%). Of 6 trials reporting functional class, all showed an improvement in 
symptoms with MRA, with average NYHA falling from 2.2 to 1.9.
Conclusion: Improvement in EF and functional class with MRA therapy are independent of baseline NYHA.
First author Age (years) Intervention Cohort (n)
Control Cohort 
(n)
Intervention Control
Follow -up 
(months)
Akbulut et al. 59 35 35 Spironlactone
Standard of care or 
Metoprolol
3
Barr et. al. 69 28 14 Spironolactone Placebo 2
Boccanelli et. al. 62 231 236 Canrenone Placebo 12
Chan et. al. 63 23 28
Spironolactone + 
Candesartan
Placebo + Candesartan 12
Cicoira et. al. 62 54 52 Spironolactone Standard of care 12
Gao et. al. 55 58 58 Spironolactone Placebo 6
Izawa et. al. 49 25 0 Spironolactone Standard of care 12
Kasama et. al. 68 25 25
Spironolactone + 
Candesartan
Placebo + Candesartan 6
Kasama et. al. 66 15 15 Spironolactone Standard of care 6
Kimura et. al. 67 11 10 Spironolactone Standard of care 12
Taheri et. al. 58 8 8 Spironolactone Placebo 6
Tsutamoto et. al. 64 20 17 Spironolactone Placebo 4
Udelson et. al. 63 177 49 Epleronone Placebo 9
Vizzardi et. al. 59 79 89 Spironolactone Placebo 6
